MSL3

Across TCGA pan-cancer cohorts, MSL3 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MSL3 data layer compared with 27 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MSL3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MSL3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, UCEC, and CESC are the cancer types where MSL3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.249	0.670	<.001	24	view →
UCEC	OS	Median	II,III,IV	1.000	0.460	.015	22	view →
CESC	DFS	Median	IV	0.053	0.529	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MSL3–LUAD (DFS)

Open the LUAD breakdown →